ORKA logo

ORUKA THERAPEUTICS INC

ORKANASDAQ
🏆 #1310 by market capEarnings Nov 10US Equity
$823.44▼ $28.41 (−3.45%)
Simulated price
🔔
Track ORKA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$5.08B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak
No chart data available for ORKA.

Trading Snapshot

Day Range
$820.17 – $839.25
52-Week Range
$15.77 – $115.52
Volume
$2.32B
Avg Volume
$1.97B
Shares Outstanding
60.3M
Next Earnings
Dec 13, 2026

Fundamentals Snapshot

Annual Revenue
$382M
Last Q Revenue
$93M
P/E Ratio
-34.1
P/S Ratio
0.0x
EPS (TTM)
$-2.11
Dividend Yield
0.00%
Dilution (1yr)
+224.1%

Why Investors Own ORKA

  • ✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ORKA logo

ORUKA THERAPEUTICS INC

ORKA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$122M▲ +38.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$88M▲ +52.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
54.4M▲ +224.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$45M▼ −$16M YoY
StockOtter · stockotter.space

About ORUKA THERAPEUTICS INC

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Ratings

ⓘ
Consensus
Buy
20 analysts
Strong Buy9
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

ORUKA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ORKA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ORUKA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.